Quantum Genesis AI Corp. (OTC: QGAI), a biotechnology company specializing in enzyme engineering and biocatalysis, released a statement on Tuesday to clarify the relationship between its research activities and those conducted by Quantumzyme LLP, a separate entity based in Bengaluru, India. The company emphasized that Quantumzyme LLP is not a subsidiary or affiliate of Quantum Genesis AI.
The clarification addresses prior press releases from November 5, 2025, and February 12, 2026, which referenced scientific publications in the company’s broader field. Those publications identified Quantumzyme LLP and reflected the affiliations of contributing researchers at the time the research was conducted. The company stated it is providing this clarification to distinguish the two entities and to offer additional context on intellectual property and technology rights transferred to Quantum Genesis AI under an Asset Purchase Agreement dated February 21, 2023, and a subsequent confirmatory assignment.
According to the company, its Chief Executive Officer, Naveen Kulkarni, transferred certain intellectual property, know-how, methodologies, processes, research and development materials, and related rights associated with the company’s core enzyme engineering and biocatalysis business under that agreement. A Current Report on Form 8-K filed on April 29, 2026, disclosed a confirmatory assignment related to intellectual property and technology associated with the company’s platform.
Quantum Genesis AI believes that the Asset Purchase Agreement transferred underlying technology, methodologies, computational approaches, and related intellectual property. Consequently, to the extent that research activities conducted by Mr. Kulkarni—whether directly or through Quantumzyme LLP—relate to the company’s core field and are based on the transferred technology, the company asserts that such intellectual property falls within the scope of the rights transferred to it.
The company’s prior disclosures regarding scientific publications were made based on its ownership of the relevant intellectual property. This clarification aims to provide transparency and ensure that stakeholders understand the distinction between Quantum Genesis AI and Quantumzyme LLP.
For more information, visit qgaicorp.com and the company’s profile on OTC Markets.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Quantum Genesis AI Clarifies Research Ties, Intellectual Property Ownership.